Advertisement

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement

Nov

12

Today In Oncology

Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC

Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib-Chemotherapy in EGFR-Positive NSCLC

Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer

Advertisement

© 2025 HSP News Service, L.L.C.